Pharmacy shelf depicting the new treatments advised on for NHS Scotland by the Scottish Medicines Consortium

Scottish Medicines Consortium publishes guidance on 12 treatments

A record-breaking month has seen the Scottish Medicines Consortium accept 11 new treatments for use in the health service.

SMC advises on newly-licensed medicines for launch in NHS Scotland and recently published guidance on a total of 12 treatments.

Included was the much-talked-about weight loss drug, semaglutide (Wegovy), which was recommended for adults when used in conjunction with diet and exercise.

Several cancer treatments were also accepted:

  • Brexucabtagene autoleucel (Tecartus) for acute lymphoblastic leukaemia
  • Olaparib (Lynparza) for some breast cancer patients
  • Regorafanib (Stivarga) for advanced colorectal cancer
  • Zanubrutinib (Brukinsa) for chronic lymphocytic leukaemia
  • Darolutamide (Nubeqa) advanced prostate cancer
                                                                          Video credit: Canva

The committee also accepted atogepant (Aquipta) for adults who have more than four migraines a month. “This is one of a number of new migraine therapies that SMC has recently approved for use in the NHS in Scotland,” said SMC chair, Dr Scott Muir.

Belzutifan (Welireg) was approved for the treatment of adults with von Hippel-Lindau disease, which is a rare genetic disorder that leaders to tumours growing in various parts of the body. Belzutifan is the first licensed medicine for the treatment of the disease.

The rare type of epilepsy known as Dravet syndrome also had a treatment accepted – fenfluramine (Fintepla) was recommended as a supplement to other anti-epileptic medicines.

SMC ruled that adults with lupus nephritis, a disease which causes the immune system to attack the kidneys, can now be treated with voclosporin (Lupkynis).

For adults who have had a transplant and are experiencing illness caused by cytomegalovirus, maribavir (Livtencity) was accepted. Cytomegalovirus leads to mild infection in healthy people but can be more serious if someone’s immune system is compromised following a transplant.

The prostate cancer treatment known as lutetium vipivotide tetraxetan (Pluvicto) was not accepted however, as the manufacturer’s clinical and cost effectiveness evidence was deemed insufficient by SMC, when compared to the current range of treatment options.

Image credit: iStock

NHE Nov/Dec 2023

NHE Nov/Dec 2023

AI is key in helping dementia patients live independently for longer.

The Nov/Dec 2023 edition of NHE brings you expert comment and analysis on a range of key health sector topics, from digital transformation to navigating post-pandemic challenges.


View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Events

NHE has created a full calendar of events to address the most important issues that influence the delivery of healthcare services. Over 365 days you'll have the opportunity to hear from a range of highly motivating, informative and inspirational speakers. These speakers will equip you with the knowledge and unique insight to enable you to overcome the challenges that you face.

National Health Executive Podcast

Ep 39.
What makes a good NHS manager? with Anthony Painter, Director of Policy at Chartered Management Institute (CMI)

In episode 39 of the National Health Executive podcast, we were joined by Anthony Painter, who is the director of policy at the Chartered Management Institute (CMI), to discuss all things management within the UK health sector and NHS.

During the podcast, Anthony shared some of the recent research CMI conducted in partnership with the Social Market Foundation, which centred around the state of management and leadership within the NHS.

More articles...

View all